581 related articles for article (PubMed ID: 28198005)
1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
[TBL] [Abstract][Full Text] [Related]
5. Warfarin pharmacogenetics.
Johnson JA; Cavallari LH
Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
[TBL] [Abstract][Full Text] [Related]
6. Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.
Sasano M; Ohno M; Fukuda Y; Nonen S; Hirobe S; Maeda S; Miwa Y; Yokoyama J; Nakayama H; Miyagawa S; Sawa Y; Fujio Y; Maeda M
Eur J Clin Pharmacol; 2019 Jul; 75(7):901-911. PubMed ID: 30852642
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
9. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
10. Race influences warfarin dose changes associated with genetic factors.
Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
[TBL] [Abstract][Full Text] [Related]
11. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
[TBL] [Abstract][Full Text] [Related]
13. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance.
Shahabi P; Scheinfeldt LB; Lynch DE; Schmidlen TJ; Perreault S; Keller MA; Kasper R; Wawak L; Jarvis JP; Gerry NP; Gordon ES; Christman MF; Dubé MP; Gharani N
Thromb Haemost; 2016 Aug; 116(2):337-48. PubMed ID: 27121899
[TBL] [Abstract][Full Text] [Related]
14. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
15. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.
Kocael A; Eronat AP; Tüzüner MB; Ekmekçi A; Orhan AL; İkizceli İ; Yılmaz-Aydoğan H; Öztürk O
Mol Biol Rep; 2019 Apr; 46(2):1825-1833. PubMed ID: 30712247
[TBL] [Abstract][Full Text] [Related]
17. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
18. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
[TBL] [Abstract][Full Text] [Related]
19. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials.
Tse G; Gong M; Li G; Wong SH; Wu WKK; Wong WT; Roever L; Lee APW; Lip GYH; Wong MCS; Liu T;
Br J Clin Pharmacol; 2018 Sep; 84(9):1868-1882. PubMed ID: 29704269
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
